Why do gastric cancers resist PD-1 plus antiangiogenesis? Spatial and plasma profiling points to M2 macrophages
Can an oncolytic virus turn “cold” sarcomas hot? Intratumoral JX-594 with avelumab raised CD8 T cells but not responses
Does metronomic trabectedin reprogram the sarcoma immune microenvironment? A macrophage-and-T-cell shift that tracks with better outcomes
Can blocking PRMT5 starve sarcomas of energy? Inhibiting the enzyme shuts down tumor glycolysis and growth
Why IDO1 in inflamed TLS-positive lung tumors predicts immunotherapy response — and marks who might benefit from IDO1 inhibitors
Indoleamine 2,3-dioxygenase 1 is expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1/PDL1 inhibitors
Background Immune checkpoint inhibitors have revolutionized the management of patients with non-small cell lung cancer. However, most patients with advanced NSCLC display primary resistance to these treatments. Indoleamine 2,3-dioxygenase 1, or IDO1, may contribute to immune regulation by catabolizing tryptophan into several immunosuppressive metabolites, including kynurenine. This study aimed to investigate the role of IDO1 […]
How to screen for mature tertiary lymphoid structures in routine pathology — a standardized method validated across 357 tumors
Why intravenous oncolytic virus JX-594 lit up immune biomarkers but not tumor responses in HR+ breast cancer
Why the TLR4 agonist G100 boosted T cells but not PD-1 response in “cold” soft tissue sarcoma
Why systemic oncolytic virus JX-594 stirred an immune signal but not clinical benefit in soft tissue sarcoma
